O-LINKED ␤-N-ACETYLGLUCOSAMINE (O-GlcNAc) is a posttranslational modification where the monosaccharide N-acetylglucosamine is attached in a beta-linkage to serine or threonine hydroxyl groups of nuclear and cytoplasmic proteins (42) . The addition of O-GlcNAc is catalyzed by the enzyme O-linked ␤-N-acetylglucosamine transferase (OGT), using UDP-GlcNAc, the end product of the hexosamine biosynthesis pathway, as substrate (21) . It is removed by ␤-N-acetylglucosaminidase (O-GlcNAcase). A wide variety of nuclear and cytoplasmic proteins bear this modification, including cytoskeletal and membrane components, transcription factors, hormone receptors, tumor suppressors, kinases and other signaling molecules, transcriptional and translational machinery, and nuclear pore proteins (5, 42) . O-GlcNAcylation has been suggested to be involved in transcription and translation (5) , protein-protein interaction (32) , and protein stability control (13) . High levels of O-GlcNAc modification in the cell, however, may have severe adverse effects. Increased glucose flux through the hexosamine biosynthesis pathway induces insulin resistance (16) . Overexpression of OGT in the liver causes insulin resistance and dyslipidemia in mice (49) . Streptozotocin (STZ), an O-GlcNAcase inhibitor (33) that causes O-GlcNAc accumulation, increases p53 accumulation and apoptosis of ␤-cells (23) and hippocampal pyramidal neurons (24) , suggesting a role of OGlcNAc in ␤-cell failure and Alzheimer's disease (52) . Specific overexpression of GK O-GlcNAcase (a dominant negative OGlcANcase derived from the GK rat) in the lens of mice causes cataracts as a result of elevated O-GlcNAc and impaired proteasome function (43) . The regulation of OGT and of cellular O-GlcNAc levels remains obscure. Levels of OGT mRNA, protein, and activity vary among tissues, possibly as a result of alternative RNA splicing and specific proteolysis (20) . OGT exists as a heterotrimer of two 110-kDa and one 78-kDa peptides. The 110-kDa is the catalytic subunit (12) ; it has an amino-terminal repeat domain containing 11.5 tandem tetratricopeptide repeats (TPR), a central linker/targeting domain, and a carboxyl-terminal catalytic domain (25) . OGT is modified posttranslationally by autoglycosylation and tyrosine phosphorylation. The effect of these modifications on the catalytic activity is still unclear (14) .
Heat shock proteins (Hsp) are modulated by stress conditions and are among the most highly expressed proteins in the cell (10, 15, 28) . Hsp90 is the most abundant, accounting for ϳ1-2% of total cellular proteins in unstressed cells (7) and increasing to ϳ4 -6% of cellular proteins under stress. Hsp90 assists in protein folding and refolding (3) , suppresses the aggregation of its client proteins, and acts as a protective chaperone (17, 27, 48) . The benzoquinone ansamycin (BA) antibiotic family that includes geldanamycin (GA) and herbimycin [radicicol (RA)] was first identified as tyrosine kinase inhibitors but is now known to specifically target Hsp90 (46) . Binding to the N-terminal ATP binding site of Hsp90 (11, 31, 39) , they block ATP hydrolysis and the dissociation of Hsp90 client proteins (34, 36, 38, 50) , and thus induce their ubiquitination and degradation by the proteasome (30, 35, 46) . Most of the known Hsp90 client proteins are signal transduction and transcription factors, essential for cell growth and cell proliferation.
In this study, we characterized a novel mechanism that regulates OGT and modulates O-GlcNAc modification levels in endothelial cells. We found that OGT interacts with the TPR-binding site of Hsp90. Inhibition of Hsp90 by radicicol or 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) destabilizes OGT and dramatically reduces its half-life in primary cultures of endothelial cells. Furthermore, the overall O-GlcNAc modification of cellular proteins was downregulated by Hsp90 inhibition. This novel mechanism is the first report of pharmacologic modulation of O-GlcNAc and might thus have important therapeutic potential.
MATERIALS AND METHODS
Materials. Anti-OGT antibody (H-300) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Hsp90 (␣ and ␤) antibody was purchased from BD Biosciences (San Jose, CA). AntiAkt1 antibody, anti-ErbB2 antibody, and anti-O-GlcNAc antibody CTD110.6 were from Cell Signaling (Danvers, MA). Anti-C terminus of hsc70-interacting protein (CHIP) antibody was purchased from Affinity BioReagents (Rockford, IL). PUGNAc and radicicol were from Sigma-Aldrich (St. Louis, MO). 17-AAG was purchased from LC laboratories (Woburn, MA).
Cell culture. Primary cultures of bovine arterial endothelial (BAE) cells were maintained in low glucose DMEM supplemented with 10% FBS and antibiotics. Primary cultures of human lung microvascular endothelial (HLMVE) cells were maintained in M199 media supplemented with 10% FBS and antibiotics, as reported earlier (4 After being washed with PBS twice, the cells were harvested and lysed with whole cell lysis buffer containing 50 mM Tris·HCl pH 8.0, 20% glycerol, 500 mM NaCl, 5 mM MgCl 2, 0.2 mM EDTA, 1 mM DTT, 0.5% NP-40, 0.5 mM PMSF, and a protease inhibitor cocktail (Calbiochem). Approximately 30 g of cellular proteins were resolved by SDS-PAGE. Western blots were performed with anti-OGT, RL2, or CTD110.6 (2 distinct antibodies that recognize O-GlcNAc modifications) or anti-Hsp90 antibodies. To detect OGT in the detergent-insoluble fraction, pellets of whole cell lysates were resuspended in equal volumes of 1ϫ SDS sample buffer (50 mM Tris·HCl pH 6.8, 100 mM DTT, 2% SDS, 5% glycerol, and 0.1% bromophenol blue) by sonication at low power. Suspensions were boiled for 5 min. Equal volumes were loaded for SDS-PAGE. To detect OGT expression in MEF cells, MEF CHIP ϩ/ϩ and MEF CHIP Ϫ/Ϫ cells were treated as above. Cells were harvested after overnight treatment and lysed in whole cell lysis buffer.
Protein stability assay. To test OGT stability, BAE cells were treated with 50 mM cycloheximide (CHX) to stop protein translation. Cells were then divided into two groups. One group was treated with 1.7 M 17-AAG, while the other group was treated with vehicle. Cells were harvested at 20-min intervals (for up to 3 h), lysed in whole cell lysis buffer, and resolved with SDS-PAGE followed by anti-OGT Western analysis. To test the effect of proteasome inhibitors on OGT stability, 1 M epoxomicin, 1 M PS341, or 10 M MG132 were applied to cultures of BAE or HLMVE cells and incubated overnight. Cells were harvest and lysed as above.
Coimmunoprecipitation. BAE cells were treated with vehicle or 2.7 M RA overnight and lysed with Hsp90 immunoprecipitation buffer containing 20 mM Tris·HCl pH 8.0, 150 mM NaCl, 0.2 mM EDTA, 10 mM Na2MoO4, 50 mM NaF, 1.5 mM Na3VO4, 10 mM ␤-glycer- ophosphate, 1% Triton X-100, 0.5 mM PMSF, and the protease inhibitor cocktail. One-hundred microliters of lysate containing 200 g cellular protein (per immunoprecipitation) were precleaned by incubation at 4°C with 2 g normal rabbit IgG for 1 h followed by 1-h incubation with 20-l protein A bead slurry. Polyclonal anti-OGT antibody (2 g ) or 2 g normal rabbit IgG were added to the precleaned lysates. The reactions were carried out at 4°C overnight. Protein A bead slurry (20 l) was added to the reaction and incubated at 4°C for another 2 h. The beads were collected by brief spinning, washed with the same lysis buffer four times, resuspended in 30-l SDS sample buffer, and boiled for 5 min. The immunoprecipitates were resolved with SDS-PAGE followed by anti-Hsp90 Western blot. Reverse immunoprecipitation was performed by adding 2 g monoclonal Hsp90 antibody or normal mouse IgG to the precleaned lysates.
After the immunoprecipitates were resolved with SDS-PAGE, anti-OGT Western blot was performed.
GST pull down assay. GST tagged fusion proteins, GST-Hsp90, GST-Hsp90-N, GST-Hsp90-M, GST-Hsp90-C, GST-OGT, GST-OGT⌬TPR(1-6), GST-OGT⌬TPR(7-12), and GST-TPR(7-12) were expressed in Escherichia coli and immobilized on glutathione agarose beads. The immobilized proteins were incubated at 4°C for 1 h with cell lysate prepared in the lysis buffer containing 20 mM HEPES-KOH pH 7.4, 20% glycerol, 300 mM NaCl, 5 mM MgCl 2, 1 mM DTT, 0.5% NP-40, and 10 mM ATP. The beads were then collected and washed four times. The proteins were eluted from the beads by the addition of 1ϫ SDS sample buffer and boiling for 3 min. Anti-OGT or anti-Hsp90 Western blot was performed.
RESULTS
OGT interacts with Hsp90. OGT contains 11.5 TPRs at its N terminus, while Hsp90 contains a TPR binding site at the C terminus. To determine whether OGT interacts with Hsp90, GST pull down assays were performed. Glutathione beads bearing GST-tagged OGT or Hsp90 was incubated with BAE cell lysates. GST-Hsp90 was able to pull down the full-length OGT from the cell lysate (Fig. 1A) , and vise versa (Fig. 1B) . These results suggest a direct interaction between OGT and Hsp90.
To determine whether OGT interacts with Hsp90 in live cells, coimmunoprecipitation experiments were performed. BAE cells were treated overnight with vehicle or RA (2.7 M). OGT was immunoprecipitated with a polyclonal OGT or control IgG antibody. Immunoprecipitates were resolved and Western blotted with Hsp90 antibody. A considerable amount of Hsp90 was immunoprecipitated by the OGT antibody (Fig.  1C) , suggesting a strong interaction between OGT and Hsp90. Reverse coimmunoprecipitation was also performed and showed clearly that the full-length OGT was coimmunoprecipitated with Hsp90 ( Fig. 1D) , although the amount of OGT immunoprecipitated by Hsp90 antibody was much less than that of Hsp90 immunoprecipitated by OGT antibody, probably because of the high cellular abundance of Hsp90. Interestingly, the Hsp90 inhibitor RA did not interfere with this interaction, suggesting that it is independent of ATP binding and hydrolysis. Also, the 78-kDa OGT isoform, the splicing variant that contains only 2.5 TPRs, was not coimmunoprecipitated with Hsp90 ( Fig. 1C) , neither was it pulled down by GST-Hsp90 (Fig. 1A) , implying a role for the N-terminal TPR motif of OGT in the interaction. No co-chaperones, such as Hsp70, Hsp70-Hsp90 organizing protein (HOP), and Hsp40 that interact with Hsp90 were coimmunoprecipitated with OGT ( Fig. 1C) . OGT interacts with the TPR binding site of Hsp90. Hsp90 consists of three highly conserved domains: a N-terminal ATP-binding domain (NTD), a middle domain (MD), and a C-terminal dimerization domain (CTD; Ref. 41) . The MD contains the catalytic loop and mediates the interaction with client proteins. The CTD contains the TPR recognition motif that mediates the interaction with TPR-containing co-chaperones. Interestingly, OGT contains 11.5 TPR motifs in its N-terminal fragment. To determine whether OGT interacts with Hsp90 through TPR, deletion mutants of both Hsp90 and OGT were expressed as GST-fusion proteins (Fig. 2, A and B) . GST pull down using different segments of Hsp90 (8) revealed that it was the 12-kDa CTD that mediated the interaction with OGT (Fig. 2C) . Consistent with the coimmunoprecipitation result (Fig. 1B) , the 78-kDa OGT was not pulled down by Hsp90 (Figs. 1D and 2C) , suggesting that the 78-kDa OGT was not involved in the interaction with Hsp90. Since the CTD contains the TPR binding motif and the 78-kDa isoform lacks most of the TPRs, this result strongly suggests that OGT interacts with Hsp90 through TPR motifs. Indeed, GST pull down using TPR deletion mutants revealed that deletion of the whole TPR fragment eliminated the interaction (Fig. 2D ). Since deletion of TPR(1-6) did not interrupt the interaction with Hsp90 (Fig. 2D) , TPR(1-6) may not be involved in the interaction with Hsp90. The interaction site may reside in TPR (7) (8) (9) (10) (11) (12) . Indeed, TPR(7-12) alone was enough to pull down Hsp90 (Fig. 2E) . Further studies are needed to identify the exact epitopes involved in the interaction of Hsp90 with TPR (7) (8) (9) (10) (11) (12) .
Hsp90 inhibition destabilizes its co-chaperones in endothelial cells. Hsp90 inhibition drives the ubiquitination and proteasome-dependent degradation of its client proteins (30, 35, 46) . Whether this occurs in vascular endothelial cells is not known. We tested the stability of Hsp90 co-chaperones in the presence of Hsp90 inhibitors in endothelial cells. Hsp90 inhibition increased the expression of Hsp70, decreased the expression of p23, but did not affect the expression of Hsp40 and HOP (Fig. 3A) . However, when protein synthesis was blocked by brief treatment with CHX, all of the above co-chaperones, including Hsp90 itself, were destabilized by the Hsp90 inhibitor 17-AAG (Fig. 3, B-F) . The same was observed with the Hsp90 client protein Akt (Fig. 3G) ; CHX, alone, did not affect the stability of these proteins. These results strongly suggest that Hsp90 inhibition is able to destabilize not only its client proteins but its cofactors as well at least in endothelial cells.
Hsp90 inhibition decreased OGT expression in primary endothelial cells. To determine whether Hsp90 inhibition decreases OGT expression, we treated BAE and HLMVE cells with the Hsp90 inhibitors RA (2.7 M) or 17-AAG (1.7 M). Compared with DMSO vehicle control, inhibition of Hsp90 by either inhibitor significantly decreased the expression of the full-length, 110 kDa, OGT (Fig. 4, A and B) in both BAE and HLMVE cells. The Hsp90 inhibitors, however, had no significant effect on the expression of the 78-kDa OGT isoform (Fig.  4, A and B) . To determine the time course of Hsp90 inhibition, BAE cells were treated with RA, and harvested from 2 to 36 h. The decrease in OGT expression was observed as early as 2 h after RA treatment (Fig. 4C) , suggesting that the effect of the Hsp90 inhibitors on OGT expression is very fast. The expression of OGT did not decrease further after 2-h treatment and remains at a steady level throughout the experimental time (Fig. 4C) , suggesting that equilibrium between protein synthesis and degradation was quickly reached.
Hsp90 inhibition decreased O-GlcNAcylation in primary endothelial cells. Knockdown of OGT by small interfering RNA decreases O-GlcNAc modification (52) . Since expression of OGT is decreased by Hsp90 inhibition, we hypothesized that the overall O-GlcNAc modification in the cell should be decreased as well. To test this hypothesis, lysates from the above-treated cells were resolved and probed for O-GlcNAc modification with RL2, a monoclonal antibody that detects O-GlcNAc modification in proteins. Treatment with Hsp90 inhibitors not only decreased OGT expression but also decreased overall O-GlcNAc modification significantly in both BAE and HLMVE cells (Fig. 5, A and B) . Time-course experiments showed that the decrease in O-GlcNAc modification was observed as early as 2 h after RA treatment and remained steady for at least 36 h (Fig. 5C) , similar to the changes in OGT expression (Fig. 4C) .
Hsp90 inhibition destabilizes OGT. To further examine whether Hsp90 inhibition destabilizes cellular OGT, CHX was applied to block protein synthesis while cells were treated with Hsp90 inhibitors and were harvested at 20-min intervals. In the presence of CHX, RA decreased the expression of the mature OGT proteins (Fig. 6A) ; CHX alone did not cause obvious changes in OGT protein level (Fig. 6B) . To eliminate the possibility that the decreased OGT level is the result of cell death caused by the combined RA and CHX treatment, cells were treated with CHX in the absence or presence of RA, harvested at 180 min, and stained with trypan blue. No significant changes in cell viability were observed (91.4% for vehicle control, 92.9% for CHX and 91.6% for combined CHX and RA treatment). These results suggest that Hsp90 inhibition destabilized OGT and reduced its half-life. The decrease in OGT expression occurred in a time-dependent manner, similar to that of the Hsp90 co-chaperones, Hsp70, HOP, Hsp40, and p23 (Fig. 3) . The degradation of OGT occurred at the same pace as that of the Hsp90 co-chaperones.
The degradation of OGT is dependent on the proteasome. The degradation of most Hsp90 client proteins occurs via the ubiquitin-proteasome system (30, 35, 46) . To determine whether the Hsp90 inhibition-induced degradation of OGT is dependent on the proteasome, we used multiple proteasomespecific inhibitors (MG132: Fig. 7 , A and B; Epo and PS-341: Fig. 7, C and D) to block cellular proteasome function in the presence of Hsp90 inhibitors (Fig. 7) . Cells were lysed with whole cell lysis buffer containing 0.5% NP-40 as the detergent. Proteins in the detergent-insoluble fraction of the lysate were dissolved in equal volumes of SDS sample buffer. As shown in Fig. 7 , A and C (bovine pulmonary artery endothelial cells), and Fig. 7 , B and D (HLMVE cells), Hsp90 inhibition decreased OGT expression, as expected. Interestingly, Hsp90 inhibition decreased OGT expression not only in the supernatant of the cell lysate but also in the detergent-insoluble fraction (Fig. 7, A-D) . The addition of proteasome inhibitors, however, did not recover OGT levels in the supernatant but caused the accumulation of OGT in the detergent-insoluble fraction instead (Fig. 7, A-D) . These results suggest that the degradation of OGT is proteasome dependent and that inhibition of Hsp90 translocates OGT to a yet unknown subcellular locus, which is resistant to 0.5% NP-40. Unlike MG132, Epo and PS-341 appear to have variable effects on the catalytically inactive 78-kDa OGT.
Degradation of OGT is independent of CHIP. The degradation of certain Hsp90 client proteins is dependent on CHIP, an E3 ubiquitin ligase that binds to Hsp90 or Hsp70, linking the chaperones to the ubiquitination apparatus (2, 6, 26) and presenting chaperone-bound misfolded proteins for ubiquitination and degradation. To determine whether Hsp90 inhibition- (Fig. 8B ). Hsp90 inhibitors decreased OGT expression to the same level as that in CHIP ϩ/ϩ MEF, indicating that CHIP might not be the E3 ligase responsible for the ubiquitination of mature OGT. Interestingly, in CHIP Ϫ/Ϫ cells, the RA or 17-AAG induced degradation of the well-known Hsp90 client proteins Akt or ErbB2 was not affected either. Unlike OGT, however, the expression of Akt and ErbB2 was much higher in CHIP Ϫ/Ϫ MEF than that in CHIP ϩ/ϩ MEF, suggesting that CHIP might be responsible for the degradation of the de novo synthesized Akt and ErbB2, but not that of the de novo synthesized OGT, nor of the mature Akt and ErbB2.
Hsp90 inhibition attenuates the increased O-GlcNAcylation induced by high glucose concentration. Increased O-GlcNAc
has been shown to induce insulin resistance (49) and ␤-cell death (23) . High glucose concentration, mimicking hyperglycemia, increases O-GlcNAc modifications. To determine whether Hsp90 inhibition reduces O-GlcNAc modification induced by high glucose, BAE and HLMVE cells were exposed to 30 mM glucose. As expected, O-GlcNAc modification in both cell types increased by high glucose (Fig. 9, A and B) .
Both Hsp90 inhibitors, RA and 17-AAG, attenuated the increase in both BAE and HLMVE cells. Notably, O-GlcNAc modification in high glucose-treated cells was reduced to about the same level as that in DMSO control by Hsp90 inhibitors. These results suggest that Hsp90 inhibitors, already in clinical use, might be used to attenuate the increased O-GlcNAc modification observed in pathological conditions such as hyperglycemia.
Inhibition of O-GlcNAcase diminishes the effect of Hsp90 inhibitors on O-GlcNAc.
To demonstrate that the decrease in O-GlcNAc is the result of the OGT degradation, we blocked the removal of O-GlcNAc by the use of PUGNAc, an inhibitor of O-GlcNAcase, which blocks the removal of O-GlcNAc modification and increases O-GlcNAc dramatically (14) . As expected, PUGNAc treatment increased O-GlcNAc in both BAE and HLMVE cells (Fig. 9, C and D) . The effect of the Hsp90 inhibitors on O-GlcNAc in the presence of PUGNAc, however, is significantly diminished compared with that under high glucose. These results suggest that the decrease in OGlcNAc caused by Hsp90 inhibition is, at least in part, the result of reduced OGT expression and activity, or in other words, the result of the change in the balance between the activities of the O-GlcNAc enzymes. To further substantiate these observations, we employed a different antibody against O-GlcNAc modification (CTD110.6). Figure 9E data confirm both the effect of high glucose concentration and that of Hsp90 inhibition on O-GlcNAcylation.
Hsp90 inhibition attenuates the increased O-GlcNAcylation of eNOS induced by high glucose concentration. eNOS, a major factor in the control of vascular function, is susceptible to hyprerglycemic O-GlcNAcylation (29) and is also a Hsp90 client protein (9) . To determine whether Hsp90 inhibition reduces eNOS O-GlcNAc modification induced by high glucose, BAE cells were exposed to 30 mM glucose. As expected, O-GlcNAc modification of eNOS was increased by high glucose after 16 h incubation, as probed by the O-GlcNAc antibody CTD110.6 (Fig. 10A) . Importantly, this increase was attenuated after treatment with the Hsp90 inhibitor 17-AAG for 3 h, at a time that 17-AAG did not affect eNOS stability (Fig.  10, A and B) . Hsp90 plays important roles in the maintenance of proteomic homeostasis by assisting in protein folding and refolding (3). Hsp90 also assists in the ubiquitination and proteasome-dependent degradation of its client proteins (30, 35, 46) , most of them signal transduction or transcription factors, essential for cell growth and cell proliferation. Inhibitors of Hsp90 induce the degradation of client proteins and exhibit potent anti-cancer effects (40, 47) . Recently, the interest in this class of drugs has been extended to other age-related diseases, such as neurodegenerative diseases and inflammation (1, 44, 45) . Hsp90 inhibitors, such as RA and 17-AAG, compete with ATP for binding to the ATP binding pocket (11, 31, 39) , block the folding process (34, 36, 38, 50) , and drive protein ubiquitination and degradation (30, 35, 46) , dramatically changing proteomic homeostasis. The flux of cellular proteins into ubiquitination requires an increase in their disposal rate to suppress their aggregation, which is toxic to the cell (17, 27, 48) . To prevent ubiquitinated protein accumulation and aggregation, the cell may respond to Hsp90 inhibition by increasing proteasome function.
The relationship between Hsp90 inhibition and proteasome function is still unclear. We recently discovered that proteasome function is under metabolic control (51) and demonstrated that OGT treatment and O-GlcNAc modification of Rpt2 inhibit proteasome function by blocking ATPase activity in the 19S regulatory cap (52) . Furthermore, inhibition of proteasome function by O-GlcNAc in lens fiber cells causes the accumulation of ubiquitinated proteins and the development of cataracts (43) . Our findings that Hsp90 inhibition downregulates OGT/O-GlcNAc protein modifications suggest a possible link between Hsp90 inhibition and proteasome stimulation. With the removal of the inhibitory effect of O-GlcNAc from Rpt2, Hsp90 inhibition may be able to promote proteasome function in a coordinated way, which is beneficial to the clearance of the ubiqutinated proteins and the prevention of aggregate formation. Indeed, we found that Hsp90 inhibition accelerated the disposal of the ubiquitinated proteins. By concomitantly accelerating protein ubiquitination and proteolysis, Hsp90 inhibition might be able to accelerate protein turnover and facilitate the clearance of abnormal or aged/damaged proteins. In this respect, occasional inhibition of Hsp90 may be able to increase overall protein quality and promotee cell survival and proper cellular function.
O-GlcNAc is elevated in hyperglycemia and has been implicated in several aspects of diabetes, such as insulin resistance (49), ␤-cell failure (23) , and diabetic complications (29, 43) . The finding that Hsp90 inhibition downregulates glucoseinduced OGT and O-GlcANc suggests intriguing therapeutic potentials for Hsp90 inhibitors in the management of diabetes by attenuating insulin resistance and delaying the development of diabetic complications. Such potential should be considered within the context of the ubiquitous nature and functions of Hsp90, since chronic use of Hsp90 inhibitors may produce unacceptable side effects. Interestingly, the side effects from chronic use of Hsp90 inhibitors in cancer have been relatively weak, possibly due to the higher affinity of inhibitors for Hsp90 in cancer cells (18) . It is not yet known whether a similarly high affinity exists towards Hsp90 in inflamed cells.
Although there are multiple protein kinases able to phosphorylate a single subset of proteins, to date there is only one OGT known to modify all of the cytoplasmic and nuclear proteins bearing this modification. How OGT recognizes so many proteins with variable amino acid sequences is unknown. OGT exhibited very strong interaction with Hsp90 ( Fig. 1, 2) , suggesting that OGT may form a stable complex with Hsp90, which has unique biological functions. Since OGT does not interact with other co-chaperones, it is unlikely that it is involved in the chaperoning process. Nonetheless, as a chaperone, Hsp90 interacts with numerous cellular proteins. The formation of a complex with Hsp90 might assist OGT in substrate recognition by facilitating the transfer of O-GlcNAc to a specific set of protein substrates. To support this notion, Hsp90 inhibition is able to induce the degradation of not only its client proteins but also the interacting co-chaperones Hsp70, Hsp40, HOP, and p23 in endothelial cells (Fig. 3) . Further investigation is required on the role of Hsp90 in the enzymatic function of OGT.
Three isoforms of OGT have been described in the cell: the full-length 110-kDa isoform, the truncated 78-kDa isoform, and the mitochondria-specific 103-kDa isoform (mOGT) (22) . The 110-and m103-kDa isoforms are enzymatically active. However, the functions of the 78-kDa and of the mitochondrial 103-kDa isoforms are still not clear. The three isoforms are distinguished by their N-terminal variations. The full-length 110-kDa OGT contains 11.5 TPRs, the 103-kDa mOGT contains 9.5 TPRs, and the 78-kDa isoform contains only 2.5 TPRs. From the GST pull-down experiments, we observed that TPRs are essential for the interaction between Hsp90 and OGT and that TPRs 7 to 12 are enough for the interaction to occur (Fig. 2, D and E) . While full-length OGT was pulled down by Hsp90, no pull-down of 78-kDa OGT was observed (Figs. 1A  and 2C ). This could be explained by the short TPR repeats at its N terminus. Although mOGT is not the focus of this study because Hsp90 is not expressed in the mitochondria of normal tissues (19) , a band resembling 103-kDa was observed between 78-kDa and the full-length 110-kDa isoforms (Figs. 1A and  2C ). This band could be the mitochondria OGT that interacts with Hsp90 in the lysate in vitro, since 9.5 TPRs is long enough to mediate the interaction. This interaction, however, may not happen in living cells.
Since its discovery in 1984 (5, 14) , the biological function of O-GlcNAc remains poorly understood. There is no OGT, nor O-GlcNAc, modification in prokaryotes. OGT and O-GlcNAc modification appear late in evolution. However, OGT is essential for multicellular eukaryotes. The intact OGT gene is required for completion of embryogenesis (37) . What makes it essential is unclear. Investigating how Hsp90 participates in the enzymatic function of OGT might help us further understand the mechanism of action of OGT, characterization of 
